Tolebrutinib Phase 2b Long-Term Extension Study
This study provides class IV evidence. It is an uncontrolled study without a comparator group.
Authors
- Jiwon Oh (ORCID: https://orcid.org/0000-0001-5519-6088)
- Conor F. Underwood (ORCID: https://orcid.org/0000-0002-8204-3738)
- Wendy Vargas (ORCID: https://orcid.org/0000-0001-8512-048X)
- Daniel S. Reich (ORCID: https://orcid.org/0000-0002-2628-4334)
- Robert J. Fox (ORCID: https://orcid.org/0000-0002-4263-3717)
- Anthony Traboulsee (ORCID: https://orcid.org/0000-0002-0351-9639)
- Deborah Dukovic
- Tiha M. Long (ORCID: https://orcid.org/0000-0002-1137-6148)
- Douglas Lorne Arnold (ORCID: https://orcid.org/0000-0003-4266-0106)
- Timothy J. Turner (ORCID: https://orcid.org/0000-0001-9770-2647)
- Sana Syed
Institutions
- Montreal Neurological Institute and Hospital (CA)
- St. Michael's Hospital (CA)
- Cleveland Clinic (US)
- University of British Columbia (CA)
- Envision Education (US)
- National Institute of Neurological Disorders and Stroke (US)
- Sanofi (United States) (US)
- NeuroRx Research (Canada) (CA)
- Pharmaxis (Australia) (AU)
- McGill University (CA)
Publication Details
- Journal
- Neurology Open Access
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1212/wn9.0000000000000028
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77